一项关于每两个月注射庚酸炔诺酮（诺孕酯）的临床试验。

A clinical trial of norethisterone oenanthate (Norigest) injected every two months.

作者信息

Howard G, Blair M, Chen J K, Fotherby K, Muggeridge J, Elder M G, Bye P G

出版信息

Contraception. 1982 Apr;25(4):333-40. doi: 10.1016/0010-7824(82)90091-9.

Abstract

A clinical trial was carried out in which Norigest (200 mg norethisterone oenanthate) was administered by intramuscular injection every 56 days into 383 women studied for 5,521 woman-months of use. No pregnancies occurred. Continuation rates at the end of one, two and three years were 76.6%, 63.7% and 33.8%. Only minor side-effects were recorded. After one year of use, 20.1% women had gained more than 2 kg in weight and 14.8% had lost more than 2 kg. There was marked disruption of the menstrual pattern and irregular bleeding was the major cause of discontinuation. In 38% of the injection intervals analysed, women were amenorrhoeic. Norigest proved an effective and acceptable method of fertility control.

摘要

进行了一项临床试验，对383名女性每56天进行一次诺瑞酯（200毫克庚酸炔诺酮）肌肉注射，研究其5521个妇女月的使用情况。未发生妊娠。1年、2年和3年末的续用率分别为76.6%、63.7%和33.8%。仅记录到轻微的副作用。使用1年后，20.1%的女性体重增加超过2千克，14.8%的女性体重减轻超过2千克。月经模式有明显紊乱，不规则出血是停药的主要原因。在分析的38%的注射间隔中，女性处于闭经状态。诺瑞酯被证明是一种有效且可接受的生育控制方法。